New Technique for Mining Health-conferring Soy Compounds
News Jul 27, 2015
In addition to inhibiting certain cancerous cells in laboratory tests, lunasin has demonstrated anti-inflammatory activity that may prove helpful in the battle against some chronic diseases. Unfortunately, obtaining sufficient amounts of lunasin has been a costly, time-consuming and laborious affair. This, in turn, has impeded lunasin’s investigation in large-scale animal and human clinical trials, according to Hari Krishnan, a molecular biologist with USDA’s Agricultural Research Service (ARS), Plant Genetics Research Unit in Columbia, Missouri.
Now, however, Krishnan and ARS colleague Thomas Wang report their development of a fast new procedure for extracting lunasin in amounts suitable to conduct these trials. Using the new procedure, they produced 3.2 grams of a concentrated form of lunasin, along with two protease inhibitors, from 100 grams of soybean flour. The actual extraction is done with a 30 percent solution of ethanol, followed by centrifuging steps and the addition of calcium chloride to further purify the concentrate, explains Krishnan. Wang leads the agency’s Diet, Genomics, and Immunology Laboratory in Beltsville, Maryland.
The entire process takes less than 2 hours and yields far more lunasin and protease inhibitor concentrate than other methods that have been tried, including sophisticated chromatography procedures and live cultures of genetically modified yeast or bacteria. Besides being faster, the new method can also be easily scaled up to yield much larger amounts.
Test-tube experiments conducted by Wang demonstrated the extract’s biological activity, inhibiting the production of inflammation-causing cytokines by human leukemia cells derived from a line called THP-1, which is commonly used in biomedical research. Their investigations coincide with increased scientific attention on the preventive role that consuming soy or soy products can play in reducing breast, colon and other cancers.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019